Acorda Therapeutics, Inc.

OTCPK:ACOR.Q Stok Raporu

Piyasa değeri: US$37.4k

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Acorda Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Acorda Therapeutics' CEO is Ron Cohen, appointed in Jan 1995, has a tenure of 29.58 years. total yearly compensation is $996.33K, comprised of 62.7% salary and 37.3% bonuses, including company stock and options. directly owns 0.6% of the company’s shares, worth $225.39. The average tenure of the management team and the board of directors is 6.3 years and 21.1 years respectively.

Anahtar bilgiler

Ron Cohen

İcra Kurulu Başkanı

US$996.3k

Toplam tazminat

CEO maaş yüzdesi62.7%
CEO görev süresi29.6yrs
CEO sahipliği0.6%
Yönetim ortalama görev süresi6.3yrs
Yönetim Kurulu ortalama görev süresi21.1yrs

Son yönetim güncellemeleri

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

May 26
Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

Recent updates

Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

Feb 21
Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Dec 18
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Jun 05
Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Acorda wins $16.5M in Ampyra arbitration case with Alkermes

Oct 17

Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote

Oct 10

Acorda inks license deal with Asieris for pre-clinical drug

Aug 29

Acorda Therapeutics announces resignation of COO

Aug 19

Acorda Therapeutics: Managing The Transition

Oct 04

Acorda Therapeutics Continues To Maneuver For A Turnaround

Jul 24

CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action

Jun 17

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

May 26
Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

Mar 09
Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

CEO Tazminat Analizi

Ron Cohen'un ücretlendirmesi Acorda Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2024n/an/a

-US$263m

Dec 31 2023US$996kUS$625k

-US$253m

Sep 30 2023n/an/a

-US$16m

Jun 30 2023n/an/a

-US$21m

Mar 31 2023n/an/a

-US$58m

Dec 31 2022US$984kUS$625k

-US$66m

Sep 30 2022n/an/a

-US$106m

Jun 30 2022n/an/a

-US$119m

Mar 31 2022n/an/a

-US$95m

Dec 31 2021US$2mUS$743k

-US$104m

Sep 30 2021n/an/a

-US$166m

Jun 30 2021n/an/a

-US$132m

Mar 31 2021n/an/a

-US$127m

Dec 31 2020US$2mUS$796k

-US$100m

Sep 30 2020n/an/a

US$49m

Jun 30 2020n/an/a

-US$222m

Mar 31 2020n/an/a

-US$232m

Dec 31 2019US$2mUS$796k

-US$273m

Sep 30 2019n/an/a

-US$329m

Jun 30 2019n/an/a

-US$79m

Mar 31 2019n/an/a

-US$6m

Dec 31 2018US$2mUS$796k

US$34m

Sep 30 2018n/an/a

-US$147m

Jun 30 2018n/an/a

-US$158m

Mar 31 2018n/an/a

-US$213m

Dec 31 2017US$2mUS$792k

-US$223m

Tazminat ve Piyasa: Ron's total compensation ($USD996.33K) is above average for companies of similar size in the US market ($USD689.66K).

Tazminat ve Kazançlar: Ron's compensation has increased whilst the company is unprofitable.

CEO

Ron Cohen (68 yo)

29.6yrs

Görev süresi

US$996,328

Tazminat

Dr. Ron Cohen, M.D., serves as an Independent Director of ZWI Therapeutics, Inc. since January 2024. He has been the Founder of Acorda Therapeutics, Inc. since 1995 and has been its Chief Executive Officer...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Ron Cohen
Founder29.6yrsUS$996.33k0.60%
$ 225.4
Michael Gesser
CFO & Treasurer2.8yrsUS$611.55k0%
$ 0
Neil Belloff
General Counsel & Corporate Secretary2.8yrsUS$661.57k0%
$ 0
Denise Duca
Executive Vice President of Human Resources9.6yrsVeri yokVeri yok
Kerry Clem
Chief Commercial Officer2.9yrsUS$592.23k0.041%
$ 15.2
Sofia Ali
Senior VP of Operations & Strategic Planningno dataVeri yokVeri yok
Susan Way
Senior VP of Drug Development & Regulatory Affairsno dataVeri yokVeri yok
Wise Young
Special Scientific Advisorno dataUS$10.00kVeri yok

6.3yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim: ACOR.Q's management team is seasoned and experienced (6.3 years average tenure).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Ron Cohen
Founder29.6yrsUS$996.33k0.60%
$ 225.4
John Varian
Independent Director2.6yrsUS$94.71k0%
$ 0
Carl Cotman
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Sandra Panem
Independent Director26.6yrsUS$82.65k0.0019%
$ 0.7
Mark Tuszynski
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Melitta Schachner
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Patrick Tresco
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Stephen Waxman
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Mary Bunge
Member of Scientific Advisory Boardno dataVeri yokVeri yok
James Fawcett
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Michael Beattie
Member of Scientific Advisory Boardno dataVeri yokVeri yok
John Kelley
Independent Non-Executive Chairman15.7yrsUS$140.22k0%
$ 0

21.1yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ACOR.Q's board of directors are seasoned and experienced ( 21.1 years average tenure).